3.40
-0.12(-3.41%)
Currency In USD
Address
460 Bourke Street
Melbourne, VIC 3000
Australia
Phone
61 3 9349 4906
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
September 29, 2003
| Name | Title | Pay | Year Born |
| David A. Stamler | CEO & Director | 744,052 | 1961 |
| Geoffrey Paul Kempler | Co-Founder & Non-Executive Chairman | 137,574 | 1955 |
| Robert Cherny | Head of Research | 0 | N/A |
| Rudolph Emile Tanzi | Chief Scientific Advisor and Member of Research & Development Advisory Board | 0 | 1958 |
| Steven D. Targum | Chief Medical Advisor | 0 | N/A |
| Abby Macnish Niven | Chief Financial Officer & Company Secretary | 0 | 1982 |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.